Last $3.74 USD
Change Today -0.02 / -0.53%
Volume 138.7K
RTIX On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

rti surgical inc (RTIX) Snapshot

Open
$3.73
Previous Close
$3.76
Day High
$3.82
Day Low
$3.67
52 Week High
06/7/13 - $4.53
52 Week Low
10/31/13 - $2.77
Market Cap
211.1M
Average Volume 10 Days
255.5K
EPS TTM
$-0.08
Shares Outstanding
56.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RTI SURGICAL INC (RTIX)

rti surgical inc (RTIX) Related Bloomberg News

View More Bloomberg News

rti surgical inc (RTIX) Related Businessweek News

No Related Businessweek News Found

rti surgical inc (RTIX) Details

RTI Surgical, Inc., together with its subsidiaries, produces and sells orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. It processes donated human musculoskeletal and other tissues, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera, and dermal tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by utilizing its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes. The company’s implants are used in the fields of spine, sports medicine, surgical specialties, bone graft substitutes and general orthopedic, dental, and ortho fixation. RTI Surgical, Inc. markets its products through its direct distribution force, as well as through a network of independent distributors to hospitals and surgeons in the United States and internationally. The company was formerly known as RTI Biologics, Inc. and changed its name to RTI Surgical, Inc. in July 2013. RTI Surgical, Inc. was founded in 1997 and is headquartered in Alachua, Florida.

1,100 Employees
Last Reported Date: 03/10/14
Founded in 1997

rti surgical inc (RTIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $547.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $332.3K
Executive Vice President of North American Sa...
Total Annual Compensation: $327.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $330.1K
Executive Vice President of Administration an...
Total Annual Compensation: $328.4K
Compensation as of Fiscal Year 2013.

rti surgical inc (RTIX) Key Developments

RTI Surgical Inc. Launches Two Natural Bone Grafting Solutions at AAOS Annual Meeting

RTI Surgical Inc. announced that it is launching two new biological solutions at the American Academy of Orthopaedic Surgeons annual meeting in New Orleans. NanOss Bioactive 3D, a synthetic three dimensional bioscaffold which supports bone formation, and map3 Cellular Allogeneic Bone Graft, an implant that contains the three essential elements needed to generate and maintain new bone, will be introduced at the RTI Surgical exhibit at booth 5937 (Hall H) during the AAOS meeting. map3 cellular allogeneic bone graft is a natural and safe alternative to autograft that supports the body's innate healing mechanisms and provides the scaffold and signals for neo-vascularization and bone growth. The next-generation nanOss Bioactive 3D is an innovative solution that allows for precise placement of the graft into bony defects for a wide range of extremity and trauma surgical procedures. This advanced bone graft features a semi-rigid three dimensional scaffold consisting of porous hydroxyapatite granules suspended within a porous gelatin-based foam matrix, designed to support the body's natural bone formation process. When hydrated, nanOss Bioactive 3D becomes formable and moldable allowing the implant to conform to the defect site. NanOss Bioactive 3D consists of nano-structured crystals which have extremely high surface area providing more cell attachment sites for osteoclasts and osteoblasts resulting in potential for improved mineralization, remodeling and bone formation. Map3 chips allograft is comprised of cortical cancellous chips, de-mineralized bone matrix and viable adult stem cells based on the multipotent adult progenitor (MAPC) cell technology. Map3 supplies the three essential elements necessary for bone formation in a single allograft. MAPC-class cells, a specific type of stem cell, are known to have osteogenic and angiogenic properties, important in supporting the bone healing process. The implant is designed for ease of use, has been processed to achieve optimal handling and is ideal for graft packing and filling bony defects.

RTI Surgical Receives CE Mark Approval for Fortiva(TM) Porcine Dermis

RTI Surgical Inc. announced that the company received approval to CE mark Fortiva(TM) Porcine Dermis and will begin distribution throughout Europe. Fortiva received 510(k) clearance from the U.S. Food and Drug and Administration (FDA) in March 2013 and was launched in the U.S. in July 2013. The implant is manufactured at RTI's Neunkirchen, Germany facility. Fortiva porcine dermis is a non-crosslinked acellular porcine dermal matrix intended for use as a soft tissue path to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue membranes. The implant is indicated for use in repairing hernias and/or body wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome. Fortiva porcine dermis is ready-to-use, requiring no rehydration or rinsing. Fortiva also aids in efficiency in the OR, with a temperature indicator for quick indication of proper storage, rounded corners for ease of suturing and consistent thickness. The implant is available in a broad array of sizes, including 35x35 cm, which represents the biologics graft available immediately. Fortiva is sterilized through RTI's Tutoplast(R) Tissue Sterilization Process, a validated chemical sterilization process that thoroughly penetrates tissue, removing antigenicity and inactivating pathogens. Terminal sterilization using low dose gamma irradiation achieves a sterility assurance level (SAL) of 10(-6).

RTI Surgical Inc. Presents at Canaccord Genuity Musculoskeletal Conference, Mar-11-2014 10:30 AM

RTI Surgical Inc. Presents at Canaccord Genuity Musculoskeletal Conference, Mar-11-2014 10:30 AM. Venue: Sheraton New Orleans Hotel, 500 Canal Street, New Orleans, Louisiana, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RTIX:US $3.74 USD -0.02

RTIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alphatec Holdings Inc $1.42 USD +0.02
Bacterin International Holdings Inc $0.70 USD +0.003
Exactech Inc $22.49 USD -0.16
ICU Medical Inc $55.98 USD -0.40
Orthofix International NV $31.51 USD +0.29
View Industry Companies
 

Industry Analysis

RTIX

Industry Average

Valuation RTIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RTI SURGICAL INC, please visit www.rtisurgical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.